PMA stands for Premarket Approval, the U.S. Food and Drug Administration’s highest-level review for high-risk medical devices. It’s a thorough evaluation to confirm a device is safe and effective before it can be sold, like a final safety inspection and license to operate. Investors care because receiving PMA can open a significant revenue stream, while delays or rejection can postpone sales and reduce a company’s value.
endovascularmedical
Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.
aortic archmedical
The aortic arch is the curved top portion of the body's main artery that carries blood from the heart and branches off to supply the brain, arms and upper body — think of it as a highway interchange where major roads split from the main route. It matters to investors because diseases, injuries or surgeries involving the aortic arch often require specialized drugs, devices or procedures that drive clinical trials, regulatory reviews, revenue opportunities and potential liability for companies in healthcare and medical technology.
chronic aortic dissectionsmedical
A chronic aortic dissection is a long-lasting tear in the inner wall of the body's main artery (the aorta) that lets blood split the wall and form a false channel, weakening the vessel over time. Like a split in a garden hose that creates a second, unstable pathway for water, it can reduce normal blood flow and raise the risk of rupture or heart strain, which matters to investors because it drives demand for long-term medical devices, drugs, hospital services, and regulatory scrutiny.
commercial launchtechnical
A commercial launch is the moment a company moves a product or service from development into full-scale sale and distribution to paying customers. It matters to investors because it usually marks the start of meaningful revenue, shows whether demand and logistics work in the real world, and can change a company’s growth and profit prospects — like a restaurant opening its doors beyond a soft preview to see if customers keep coming.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
HERZLIYA, Israel--(BUSINESS WIRE)--
Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for open surgical repair. The purchase price for the acquisition is $175M less offsets for previously provided loans, plus a potential for up to $200M in additional consideration contingent upon U.S. NEXUS commercial performance over the next two years.
For the surgical community, this marks the integration of the NEXUS system into the most comprehensive global portfolio of solutions to treat the aortic arch. By joining Artivion, Endospan’s innovative endovascular technology will be supported by a leading company in cardiac and vascular surgery, facilitating broader access to "best-in-class" solutions for most of the aortic treatment scenarios.
"The FDA approval of the NEXUS system was a pivotal moment for aortic surgeons seeking a technology specifically designed to treat the ascending and aortic arch," said Kevin Mayberry, Chief Executive Officer at Endospan. "With Artivion’s acquisition of Endospan, this differentiated technology is being positioned within a company that understands the aortic space through a differentiated portfolio serving the multidisciplinary approach of open, endo and hybrid solutions."
While Artivion prepares for the full U.S. commercial launch, the acquisition solidifies a market leading position in international markets where Endospan’s technology is already established. Artivion has acted as the exclusive distributor of the NEXUS System in EMEA since 2019. The Endospan expanded portfolio in Europe, Asia-Pacific and Latin America offers a unique breadth of solutions, ranging from off-the-shelf endovascular systems to custom-made multibranch configurations of NEXUS DUO and NEXUS TRE.
“Our acquisition of Endospan and its NEXUS system completes our market-leading, three-pronged aortic arch portfolio. This technology, alongside AMDS and ARCEVO LSA, positions us at the forefront of this segment as the only company globally with a complete portfolio of aortic arch solutions," said Pat Mackin, Artivion Chairman, President, and Chief Executive Officer. "Further, NEXUS is a platform technology, not just a single product. With this acquisition, we are also adding a robust pipeline of next-generation arch technologies currently in development that we expect will further expand and strengthen our leadership position in the aortic arch market over time.”
About Endospan
Privately held Endospan, headquartered in Herzliya (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan’s NEXUS® Aortic Arch Stent-Graft System was the first endovascular off-the-shelf system with CE Mark to treat an underserved group of patients diagnosed with a dilative lesion in, or near, the aortic arch and ascending expanding minimally invasive endovascular repair in this anatomical region. For additional information about Endospan, visit its website at www.endospan.com.
About Artivion, Inc. Headquartered in suburban Atlanta, Georgia, Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.
